18th Meet The Professor. Advanced International Breast Cancer Course (AIBCC) - Digital Event
Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.
As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.
New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, tio allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.
The 18th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.
10.15 Introduction to the Conference Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION
Chairpersons: Hesham Ahmed Gaballah Elghazaly, Aleix Prat
10.30 Biological heterogeneity and clinical outcomes in HR+/HER2-negative disease Maria Vittoria Dieci 11.00 PDL1, TMB, TROP2, immune infiltration and genomic classifiers in TNBC Giampaolo Bianchini 11.30 Is HER2-low breast cancer a real entity? Scoring issues and biological heterogeneity Giuseppe Viale 12.00 HER2+ early breast cancer: potential role of genomic classifiers Aleix Prat 12.30
13.00 Lunch SESSION II – CHANGING PARADIGMS FOR LOCOREGIONAL TREATMENTS MASTECTOMY, BREAST RECONSTRUCTION AND RADIATION THERAPY
Chairpersons: Jaceck Jassem, Philip Poortman
14.00 When is breast-conserving therapy really not avoidable Oreste Davide Gentilini 14.30 Breast reconstruction: when and how? Vincenzo Vindigni 15.00 Radiation therapy after breast reconstruction Orit Kaidar-person 15.30
Multidisciplinary Tumor Board 1 – Locoregional treatment
Panelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Fedro Peccatori
16.00 Clinical case 1. Second breast conserving therapy Tania Saibene 16.15 Clinical case 2. Patient with lymph node seen on planning CT-scan: what now? (RT) Silvia Michieletto 16.30 Clinical case 3: BOOP: after or due to radiation therapy Luca Visani 16.45 Concluding comments Eleftherios Mamounas, Fedro Alessandro Peccatori 17.00
17.45 Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2022 18.00 Lecture of the Awardee 18.30
SESSION III – EARLY BREAST CANCER. FINE TUNING FROM DE-ESCALATION TO ESCALATION
Chairpersons: Pierfranco Conte, Miguel Martin
9.00 Tailoring neoadjuvant/adjuvant treatment for triple negative breast cancer Sibylle Loibl 9.30 Risk adapted treatment of early HR+/HER2- breast cancer: from modulation of endocrine treatment to novel agents Stephen Johnston 10.00 Is there a role for anthracyclines in contemporary treatment of early breast cancer? Valentina Guarneri 10.30
11.00 Coffee Break Multidisciplinary Tumor Board 2 - Early breast cancer
Panelists: Bettina Borisch, Pierfranco Conte, Valentina Guarneri, Jacek Jassem, Stephen Johnston, Sibylle Loibl, Miguel Martin, Fedro Peccatori
11.30 Clinical case 1. Node positive, premenopausal patient: role of genomic classifiers Cristina Falci 11.45 Clinical case 2. HR+HER2+ patient with residual disease after neoadjuvant therapy Federica Miglietta 12.00 Clinical case 3. Adjuvant treatment in rare histologies Grazia Vernaci 12.15 Concluding comments Jacek Jassem, Miguel Martin 12.30 Lunch SESSION IV – METASTATIC BREAST CANCER: NEW OPTIONS, NEW ALGORITHMS
Chairpersons: Bettina Borisch, Alessandra Gennari
13.30 HER2+ advanced breast cancer: new treatment algorithms Sandra Swain M 14.00 TN advanced breast cancer: biology-driven treatment algorithms Hope Rugo 14.30 HR+ advanced breast cancer: what after CDK4/6? Giuseppe Curigliano 15.00
Multidisciplinary Tumor Board 3 – Metastatic Breast Cancer
Panelists: Bettina Borisch, Pierfranco Conte, Giuseppe Curigliano, Hesham Ahmed Gaballah Elghazaly, Hope Rugo, Sandra Swain
15.30 Clinical case 1. Brain metastases Gaia Griguolo 15.45 Clinical case 2. Possibility of discontinuing treatment in very long term responders Carlo Alberto Giorgi 16.00 Clinical case 3. Locoregional treatment for oligometastatic disease or role of NGS in ABC Michele Bottosso 16.15 Concluding comments Pierfranco Conte, Hesham Ahmed Gaballah Elghazaly 16.30
Take home messages and adjourn
Participation registration fees
- For physicians € 180.00
- For graduate students and nurses € 100.00
For eligibility criteria and other information on reduced fees (if applicable), contact email@example.com.
To participate in the event, it is necessary to complete the registration procedure (including payment of the applicable fee). Payment can be made online exclusively with Credit Cards or Paypal.
If the minimum number of participants is not reached, the Academy reserves the right to cancel the activity. In this case, Accademia will proceed with the appropriate communication and full refund of the participation fees.
In case of withdrawal, please inform AccMed promptly. If the waiver occurs within the 10th day prior to the start date of the event, the amount paid will be returned with the deduction of 30%. If the waiver occurs after that deadline, no reimbursement will be provided.
Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere
The credit certification for the webinar is subject to:
- Professions/specializations should correspond to those which have been accredited for CME;
- attendance at the live webinar on the platform fad.accmed.org;
- the completion of the Meeting evaluation online form;
- completion of the final test (at least 75% of correct answers). 5 attempts admitted. The test and the meeting evaluation form must be completed within 3 days from the end of the event.